A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase
- 7 December 1995
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 5 (23) , 2829-2834
- https://doi.org/10.1016/0960-894x(95)00495-f
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Design of Enediyne ProdrugsSynlett, 1995
- Antibody-Directed Enzyme Prodrug TherapyClinical Pharmacokinetics, 1994
- Self-Immolative Prodrugs: Candidates for Antibody-Directed Enzyme Prodrug Therapy in Conjunction with a Nitroreductase EnzymeJournal of Medicinal Chemistry, 1994
- Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugatesTrends in Biotechnology, 1994
- The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)Cancer and Metastasis Reviews, 1993
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—II: A comparison of an Escherichia coli nitroreductase and Walker DT diaphoraseBiochemical Pharmacology, 1992
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—IBiochemical Pharmacology, 1992
- Site-specific atom transfer from DNA to a bound ligand defines the geometry of a DNA-calicheamicin .gamma.1I complexJournal of the American Chemical Society, 1990
- Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1IJournal of the American Chemical Society, 1987
- Reactive 1,4-dehydroaromaticsAccounts of Chemical Research, 1973